Campaigners furious as Build Back Better framework drops action on drug prices

29 October 2021
biden_big-1

US President Joe Biden was never going to please everyone in announcing the framework for his Build Back Better Agenda and Bipartisan Infrastructure Bill, but the absence of provisions to lower drug prices is an issue that has caused particular anger among some Americans.

A plan that would have permitted Medicare to use its bargaining power to lower the price of prescription drugs for Americans has been dropped from the $1.75 trillion proposal, with Senator Kyrsten Sinema angering many of her fellow Democrats by opposing the measures to make medicines cheaper.

While some blame her for killing the plan, the issue is increasing the heat on President Biden, whose party was elected on a platform of drug pricing reform. As other presidents before him have discovered, the reality of delivering on that promise can be very difficult to achieve.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical